OPKO Health Inc (OPK) Price

OPKO Health Bets on Pipeline as Stock Trails Industry by 15.7%

OPKO Health is relying on its drug pipeline and the performance of its flagship renal therapy, RAYALDEE, for growth in 2026, even as its stock has declined 4.5% over the past six months.